207 related articles for article (PubMed ID: 23045294)
1. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
[TBL] [Abstract][Full Text] [Related]
2. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
Watzka SB; Posch F; Pass HI; Huflejt M; Bernhard D; Hannigan GE; Müller MR
J Thorac Cardiovasc Surg; 2011 Aug; 142(2):384-9. PubMed ID: 21620418
[TBL] [Abstract][Full Text] [Related]
3. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Canessa PA; Chella A; Lucchi M; Mussi A; Mutti L
Int J Biol Markers; 2010; 25(3):164-70. PubMed ID: 20878622
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
10. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
13. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
14. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
Watzka SB; Setinek U; Stubenberger EB; Tötsch M; Dekan G; Marcher M; Fleck T; Müller MR
Eur J Cardiothorac Surg; 2011 Feb; 39(2):180-4. PubMed ID: 20580243
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
16. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
17. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
18. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
[TBL] [Abstract][Full Text] [Related]
19. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
20. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
